Outset Medical, Inc. achieved a notable revenue rebound in fiscal year 2025 alongside FDA clearance for its next-generation Tablo Hemodialysis System, signaling market momentum after prior setbacks. The company’s manufacturing strategy—anchored in an insourced Mexican facility operated with TACNA and supported by Southeast Asia contract manufacturing—balances cost control with supply chain risks. Despite improved liquidity and strong current ratios, Outset continues to post significant net losses, navigating regulatory uncertainties and external operational threats. The proprietary Tablo system remains a key moat, but ongoing innovation and careful execution will be critical to sustaining growth in the competitive dialysis device market.